Longeveron (LGVN) Net Cash Flow (QoQ) (2020 - 2026)
Longeveron (LGVN) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Longeveron |
20.35 Bn |
20.33 Bn |
264,000.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
342.13% |
| Dec 31, 2025 |
-320.46% |
| Sep 30, 2025 |
72.70% |
| Jun 30, 2025 |
18.59% |
| Mar 31, 2025 |
-38.32% |
| Dec 31, 2024 |
-134.09% |
| Sep 30, 2024 |
-0.31% |
| Jun 30, 2024 |
446.79% |
| Mar 31, 2024 |
-200.91% |
| Dec 31, 2023 |
482.31% |
| Sep 30, 2023 |
65.13% |
| Jun 30, 2023 |
59.47% |
| Mar 31, 2023 |
-79.71% |
| Dec 31, 2022 |
53.82% |
| Sep 30, 2022 |
-248.53% |
| Jun 30, 2022 |
45.89% |
| Mar 31, 2022 |
-122.15% |
| Dec 31, 2021 |
324.38% |
| Sep 30, 2021 |
-138.81% |
| Jun 30, 2021 |
-112.57% |
